The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.
  | Hollevoet, K., Nackaerts, K., Gosselin, R., De Wever, W., BOSQUEE, L., De Vuyst, P., Germonpré, P., Kellen, E., Legrand, C., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. P. (November 2011). Soluble Mesothelin, Megakaryocyte Potentiating Factor and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma. Journal of Thoracic Oncology, 6 (11), 1930-1937. doi:10.1097/JTO.0b013e3182272294  Peer Reviewed verified by ORBi |
 | Hollevoet, K., Van Cleemput, J., Thimpont, J., De Vuyst, P., BOSQUEE, L., Nackaerts, K., Germonpré, P., Vansteelandt, S., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. (May 2011). Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals. Journal of Thoracic Oncology, 6 (5). doi:10.1097/JTO.0b013e31820db377 Peer Reviewed verified by ORBi |
  | BOSQUEE, L. (2011). Importance des inhibiteurs de la thyrosine kinase. Vaisseaux, Coeur, Poumons. |
 | Thonnard, A.-S., BOSQUEE, L., & CORHAY, J.-L. (2011). Le cas clinique du mois. Cancer bronchique avance non a petites cellules avec reponse exceptionnelle aux therapies ciblees. Revue Médicale de Liège, 66 (3), 121-5. Peer reviewed |
 | Nepper, S., Frusch, N., Louis, R., Ghaye, B., de Leval, L., & BOSQUEE, L. (2010). Pneumopathies organisées: à propos de 3 cas. Revue Médicale de Liège, 65 (10), 549-55. Peer reviewed |
 | Bosquee, L. (2010). Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC) [Poster presentation]. 2010 ASCO - Annual Meeting, Chicago, United States. |
 | Hollevoet, K., Thimpont, J., Germonpré, P., BOSQUEE, L., De Vuyst, P., Legrand, C., Kellen, E., Kishi, Y., Delanghe, J. R., & Van Meerbeeck, J. P. (2010). Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 181, 620-625. doi:10.1164/rccm.200907-1020OC Peer Reviewed verified by ORBi |
 | Bosquee, L. (August 2009). Niet-kleincellige longkanker : classificatie van de "International Association for Study of Lung Cancer" (IASLC) 2007. Tempo Médical, 314, 23-26. |
 | Valdes Socin, H. G., Niaourou, V., Vandeva, S., Bosquee, L., & Beckers, A. (2009). Syndromes paranéoplasiques endocriniens: diagnostic et prise en charge. Revue Médicale Suisse, 5 (214), 1668-74. Peer Reviewed verified by ORBi |
 | Zatloukal, P., Gervais, R., Vansteenkiste, J., Bosquee, L., Sessa, C., Brain, E., Dansin, E., Urban, T., Dohollou, N., Besenval, M., & Quoix, E. (August 2008). Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. Journal of Thoracic Oncology, 3 (8), 894-901. doi:10.1097/JTO.0b013e31817e6669 Peer Reviewed verified by ORBi |
 | Allan, S., BOSQUEE, L., Franke, A., Pirker, R., & Scagliotti, G. (May 2008). Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study. American Journal of Clinical Oncology, 26 (20). Peer Reviewed verified by ORBi |
 | Coucke, P., Barthelemy, N., Bosquee, L., & Van Meerbeeck. (2008). Is an evidence-based approach unrealistic in NSCLC? Belgian Journal of Medical Oncology, volume 2 (6), 326-333. Peer Reviewed verified by ORBi |
 | Bosquee, L., Frusch, N., & Louis, R. (29 August 2007). Prise en charge du cancer pulmonaire non a petites cellules. Revue Médicale Suisse, 3 (122), 1890-5. |
 | Kim, E. S., & Bosquee, L. (June 2007). The importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer: An update on available techniques. Journal of Thoracic Oncology, 2 (6, Suppl. S), 59-S67. doi:10.1097/01.JTO.0000269738.13586.fd Peer Reviewed verified by ORBi |
 | Talbot, D. C., von Pawel, J., Cattell, E., Yule, S. M., Johnston, C., Zandvliet, A. S., Huitema, A. D. R., Norbury, C. J., Ellis, P., Bosquee, L., & Reck, M. (15 March 2007). A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 13 (6), 1816-1822. doi:10.1158/1078-0432.CCR-06-0249 Peer Reviewed verified by ORBi |
 | van Puijenbroek, R., Bosquee, L., Meert, A. P., Schallier, D., Goeminne, J. C., Tits, G., Collard, P., Nackaerts, K., Canon, J. L., Duplaquet, F., Galdermans, D., Germonpré, P., Azerad, M.-A., Vandenhoven, G., De Greve, J., & Vansteenkiste, J. (January 2007). Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. European Respiratory Journal, 29 (1), 128-33. doi:10.1183/09031936.00050706 Peer Reviewed verified by ORBi |
 | Louis, R., Bosquee, L., DUYSINX, B., & Corhay, J.-L. (2007). Actualites therapeutiques en pneumologie. Revue Médicale de Liège, 62 (5-6, May-Jun), 288-92. Peer reviewed |
 | Frusch, N., Bosquee, L., & Louis, R. (2007). Le cancer du poumon. Epidemiologie et facteurs etiologiques. Revue Médicale de Liège, 62 (9), 548-53. Peer reviewed |
 | Barthelemy, N., Rinken, F., Dekoster, G., & Bosquee, L. (November 2006). Efficacy and Morbidity of a Novel Induction Treatment in Locally Advanced Non Small Cell Lung Cancer (NSCLC). International Journal of Radiation, Oncology, Biology, Physics, 66 (3), 476-S477. doi:10.1016/j.ijrobp.2006.07.890 Peer Reviewed verified by ORBi |
 | Scagliotti, G. V., Smit, E., Bosquee, L., O'Brien, M., Ardizzoni, A., Zatloukal, P., Eberhardt, W., Smid-Geirnaerdt, M., de Bruin, H. G., Dussenne, S., Legrand, C., & Giaccone, G. (October 2005). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 50 (1), 91-96. doi:10.1016/j.lungcan.2005.05.012 Peer Reviewed verified by ORBi |
 | Schleich, F., Bustin, F., Bosquee, L., & Legros, J.-J. (September 2005). Diabete insipide dans le cadre d'un carcinome pulmonaire a petites cellules: un paradoxe? Annales d'Endocrinologie, 66 (4), 355-60. doi:10.1016/S0003-4266(05)81793-7 Peer Reviewed verified by ORBi |
 | Bosquee, L., Rinken, F., Bustin, F., Gustin, M., Broux, R., Angelescu, S., Dekoster, G., & Barthelemy, N. (July 2005). Efficacy and morbidity of a novel induction treatment for locally advanced NSCLC. Lung Cancer, 49 (Suppl. 2), 78. doi:10.1016/S0169-5002(05)80373-3 Peer Reviewed verified by ORBi |
 | van Puijenbroek, R., Bosquee, L., Tits, G., Germonpre, P., Strobbe, E., & Vansteenkiste, J. (July 2005). Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 49 (Suppl. 2), 273. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., & Quaedvlieg, V. (August 2003). Phase II trial exploring gemcitabine and cisplatin as treatment of patients with non-small cell lung cancer (NSCLC) and inoperable brain metastases. Lung Cancer, 41 (supp2), 145. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., Bartsch, P., Deneufbourg, J.-M., Albert, A., & Nusgens, B. (August 2003). Interleukin-6 and transforming growth factor-beta1 are increased in bronchoalveolar lavage fluid following thoracic radiotherapy. Lung Cancer, 41 (supp2), 173. Peer Reviewed verified by ORBi |
 | Vansteenkiste, J., Vandebroek, J., Nackaerts, K., Dooms, C., Galdermans, D., Bosquee, L., Delobbe, A., Deschepper, K., Van Kerckhoven, W., Vandeurzen, K., Deman, R., D'Odemont, J. P., Siemons, L., Van den Brande, P., & Dams, N. (May 2003). Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer, 40 (2), 191-199. doi:10.1016/S0169-5002(02)00515-9 Peer Reviewed verified by ORBi |
 | Mommens, V., Bosquee, L., & D'Orio, V. (March 2003). Toxicite pulmonaire de la gemcitabine dans le cadre d'un CPNPC avec carcinomatose cerebrale. Revue Médicale de Liège, 58 (3), 123-6. Peer reviewed |
 | Ardizzoni, A., Manegold, C., Debruyne, C., Gaafar, R., Buchholz, E., Smit, E. F., Lianes, P., ten Velde, G., Bosquee, L., Legrand, C., Neumaier, C., King, K., & Giaccone, G. (January 2003). European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical Cancer Research, 9 (1), 143-150. Peer Reviewed verified by ORBi |
 | Barthelemy, N., David, J.-L., Bosquee, L., Bury, T., Seidel, L., Albert, A., Bartsch, P., BAUGNET-MAHIEU, L., & Deneufbourg, J.-M. (March 2002). Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms. European Journal of Clinical Investigation, 32 (3), 193-198. doi:10.1046/j.1365-2362.2002.00956.x Peer Reviewed verified by ORBi |
 | Sautois, B., Fraipont, V., Baudoux, E., Fassotte, M.-F., Hermanne, J. P., Jerusalem, G., Bours, V., Bosquee, L., Schaaf-Lafontaine, N., Paulus, J.-M., Sondag, D., Fillet, G., & Beguin, Y. (1999). Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica, 84 (4), 342-9. Peer Reviewed verified by ORBi |
 | Barthelemy, N., Bosquee, L., Baugnet, Bartsch, P., & Deneufbourg, J.-M. (1997). Pulmonary function changes in patients with lung cancer treated by combined radiation and chemotherapy. Lung Cancer. Peer Reviewed verified by ORBi |
